|
|
OVATIO™ DR Dual Chamber, model number 6550
Compact Intelligence
PARAD+TM Superior specificity
SafeRTM 99.9%3 intrinsic conduction
OVATIO DR™ can detect and treat the full spectrum of tachyarrhythmias with painless antitachycardia pacing (ATP). OVATIO DR™ offers ICD recipients the comfort of painless therapy, significantly improving their quality of life by terminating the slowest (100 bpm) as well as fastest (up to 255 bpm) ventricular tachyarrhythmias and lowering the risk of delivering unnecessary defibrillation shocks. Its main features include SafeR and PARAD+. SafeR is a pacing mode that monitors AV conduction and promotes natural heart function by limiting unnecessary stimulation of the right ventricle. PARAD+ protects patients against inappropriate shocks, which may be delivered in response to misclassified supraventricular tachyarrhythmias. OVATIO DR™ is the smallest dual-chamber ICD currently available (29 cc). Essential for patients who need more energy to terminate life-threatening arrhythmias, OVATIO DR™ offers 34 J of maximum output. OVATIO DR™ is also optimally shaped and durable, offering ease of implantation and long-term patient comfort. AIDA Enhanced follow-ups
AIDA+, clinic time focused on quality
Example: What type of AV block occurred?
Dual chamber EGM and markers. Example: Did AV conduction change over time?
Example: Which type of arrhythmias and therapies did the patient experience?
Intended uses, warnings and precautions
1. 99% overall specificity with "out-of-the box settings". Hintringer F et al: Comparison of the specificity of implantable dual chamber defibrillator detection algorithms. PACE 2004;27:976-982. 2. Unique long cycle search criteria is used to avoid treating AF that is rapidly conducted to the ventricle, and thus limits inappropriate therapies for AF to 0.3% to 0.8% risk per patient. Mletzko R et al: Enhanced Specificity of a Dual Chamber ICD Arrhythmia Detection Algorithm by Rate Stability criteria. PACE 2004;27:1113-1119. 3. “99.9% intrinsic AV conduction in 28/35 (80%) of patients of non-selected DDD patients” Anselme et al. First clinical results of AAIsafeR2, a new mode to prevent ventricular pacing. Heart Rhythm 2006; 2, supp 5; p4-99 (abs). 4. Based on September 2007 data |
|


Newsroom RSS feed